Leadership - Management

Epizyme®‘s management team is composed of proven biopharma executives with a passion for creating innovative therapeutics for patients. A highly complementary team, we are proud to lead Epizyme’s exceptional organization.

Robert J. Gould, Ph.D.
President and Chief Executive Officer 

Robert J. Gould, Ph.D. has served as a director since March 2008 and our President and Chief Executive Officer since March 2010. Prior to joining Epizyme, from November 2006 to March 2010, Dr. Gould served as Director of Novel Therapeutics at The Broad Institute of MIT and Harvard, a research institute. Prior to that, Dr. Gould was Vice President, Licensing and External Research, Merck Research Laboratories, at Merck & Co., Inc., a healthcare company, where he held a variety of leadership positions during his 20-year tenure. Dr. Gould received a B.A. from Spring Arbor College and a Ph.D. from The University of Iowa and undertook post-doctoral studies at The Johns Hopkins University. To learn more from Robert Gould, watch his video here: http://youtu.be/ov9c8CroOH4


Robert A. Copeland, Ph.D.
President of Research and Chief Scientific Officer

Robert A. Copeland, Ph.D. has served as our President of Research and Chief Scientific Officer since September 2008. Prior to joining Epizyme, Dr. Copeland was Vice President, Cancer Biology, of the Oncology Center of Excellence in Drug Discovery at GlaxoSmithKline (GSK). Before joining GSK, Dr. Copeland held scientific staff positions at Merck Research Laboratories of Merck and Bristol-Myers Squibb Company, a biopharmaceutical company, and a faculty position at the University of Chicago Pritzker School of Medicine. Dr. Copeland received a B.S. in chemistry from Seton Hall University, a Ph.D. in chemistry from Princeton University and did postdoctoral studies as the Chaim Weizmann Fellow at the California Institute of Technology. To learn more from Robert Copeland, watch his video here: http://youtu.be/npAwbtCyaS0
Back to Top

Peter Ho, M.D., Ph.D.
Chief Development Officer

Peter Ho, M.D., Ph.D. has served as Chief Development Officer since September 2014. His prior pharmaceutical positions included Vice President of Oncology Development at Johnson & Johnson and Senior Vice President, Oncology Center of Excellence for Drug Development at GlaxoSmithKline. Dr. Ho is a board-certified pediatric hematologist/oncologist and was formerly a fellow at the Dana-Farber Cancer Institute, the National Cancer Institute (NCI) and the US Food and Drug Administration (FDA). He received a B.A. in biology from the Johns Hopkins University and an M.D. and Ph.D. (pharmacology) from the Yale University School of Medicine.
Back to Top

Andrew E. Singer
Executive Vice President and Chief Financial Officer

Andrew E. Singer has served as our Executive Vice President, Finance and Administration, Chief Financial Officer and Treasurer since February 2015. Prior to joining us, from 2004 to January 2015, Mr. Singer served in increasing levels of responsibility in the Health Care Investment Banking Group at RBC Capital Markets Corporation, or RBC, an investment bank, serving as a Managing Director from 2007 to 2015. Prior to joining RBC, Mr. Singer worked at Petkevitch & Company, co-founded MVC Capital, and worked at Robertson, Stevens & Co, The Shansby Group and The Blackstone Group. Mr. Singer serves on the board of directors of the J.F. Kapnek Trust. Mr. Singer received a B.A. from Yale University and an M.B.A. from Harvard University Graduate School of Business.
Back to Top